Anthony Dimitrov

Summary

Publications

  1. ncbi request reprint Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection
    Anthony Dimitrov
    Profectus BioSciences Inc, Techcenter at UMBC, Room 4011, 1450 South Rolling Road, Baltimore, MD 21227, USA
    Curr Opin Investig Drugs 8:653-61. 2007
  2. pmc Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection
    Yongjun Guan
    Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 106:3952-7. 2009

Research Grants

Collaborators

Detail Information

Publications2

  1. ncbi request reprint Ibalizumab, a CD4-specific mAb to inhibit HIV-1 infection
    Anthony Dimitrov
    Profectus BioSciences Inc, Techcenter at UMBC, Room 4011, 1450 South Rolling Road, Baltimore, MD 21227, USA
    Curr Opin Investig Drugs 8:653-61. 2007
    ..Ibalizumab had reached phase II clinical trials; however, there are currently no ongoing clinical trials...
  2. pmc Discordant memory B cell and circulating anti-Env antibody responses in HIV-1 infection
    Yongjun Guan
    Division of Basic Science, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Proc Natl Acad Sci U S A 106:3952-7. 2009
    ..These data suggest that plasma Ab repertoires can underestimate the breadth of humoral immunity, and analyses of B(Mem) should be included in studies correlating Ab specificity with protective immunity to HIV-1...

Research Grants2

  1. Rapamycin Enhanced Efficiency of Anti-HIV Antibodies
    Antony Dimitrov; Fiscal Year: 2007
    ..The objective of this Phase I SBIR proposal is to identify potential combinations of rapamycin and antiviral antibodies that may have clinical potential. [unreadable] [unreadable] [unreadable]..
  2. Rapamycin enhanced efficacy of small-molecule HIV entry inhibitors
    Antony Dimitrov; Fiscal Year: 2008
    ..Preclinical and clinical development of such combinations will be the subject of follow-on SBIRs. [unreadable] [unreadable] [unreadable]..